Chronic lymphocytic leukaemia: open trials in Canada

23 open trials have a site in Canada. Registry data; only the trial team decides who can take part.

NCT05947851
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre (Site 1402), Greenfield Park · Kingston Health Sciences Centre-Kingston General Hospital Site (Site 1416), Kingston · The Moncton Hospital (Site 1414), Moncton · Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer (Site 1410), Sherbrooke
Registry updated 2026-11-06
NCT04269902
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Trial Treatment · Phase 3 · National Cancer Institute (NCI)
QEII Health Sciences Centre/Nova Scotia Health Authority, Halifax · Jewish General Hospital, Montreal · Lakeridge Health Oshawa, Oshawa · Ottawa Hospital and Cancer Center-General Campus, Ottawa · Allan Blair Cancer Centre, Regina · Atlantic Health Sciences Corporation-Saint John Regional Hospital, Saint John · BCCA - Vancouver Cancer Centre, Vancouver · CancerCare Manitoba, Winnipeg
Registry updated 2026-11-05
NCT06588478
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Trial Treatment · Phase 2 · Loxo Oncology, Inc.
Royal Victoria Regional Health Centre, Barrie · Saskatoon Cancer Centre, Saskatoon
Registry updated 2026-11-04
NCT07218341
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Trial Treatment · Phase 4 · Eli Lilly and Company
Princess Margaret Cancer Centre - University Health Network, Toronto
Registry updated 2026-11-04
NCT04728893
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Trial Treatment · Phase 2 · Merck Sharp & Dohme LLC
Arthur J.E. Child Comprehensive Cancer Centre (Site 0401), Calgary · CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont (Site 0403), Montreal · Jewish General Hospital (Site 0400), Montreal · The Ottawa Hospital (Site 0404), Ottawa · Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology (Site 0406), Toronto
Registry updated 2026-10-27
NCT06943872
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Trial Treatment · Phase 3 · BeOne Medicines
Arthur Je Child Comprehensive Cancer Centre, Calgary · Cross Cancer Institute, Edmonton · Ciusss Nim Hscm, Montreal · The Ottawa Hospital, Ottawa · Chu de Quebec Universite Laval, Hopital de Lenfant Jesus, Centre Integre de Cancerologie (Cic), Québec · Newfoundland and Labrador Health Services, St. John's · Princess Margaret Cancer Centre, Toronto · British Columbia Cancer Agency the Vancouver Centre, Vancouver · CancerCare Manitoba, Winnipeg
Registry updated 2026-10-23
NCT05371808
Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:
Research · Canadian Cancer Trials Group
The Jewish General Hospital, Montreal · Lakeridge Health Oshawa, Oshawa · Ottawa Hospital Research Institute, Ottawa · Regional Health Authority B, Zone 2, Saint John · BCCA - Vancouver, Vancouver · CancerCare Manitoba, Winnipeg
Registry updated 2026-10-14
NCT06208735
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Trial Treatment · Phase 1 · British Columbia Cancer Agency
Alberta Children's Hospital, Calgary · Arthur J.E. Child Comprehensive Cancer Centre, Calgary · The Ottawa Hospital - General Campus, Ottawa · Princess Margaret Cancer Centre, Toronto · The Hospital for Sick Children, Toronto · BC Children ' s Hospital, Vancouver · Vancouver General Hospital, Vancouver
Registry updated 2026-10-14
NCT07648264
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Trial Treatment · Phase 3 · CSL Behring
Horizon Health Network, Fredericton · McGill University Health Research Institute, Montreal
Registry updated 2026-10-14
NCT06136559
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
William Osler Health System (Site 0103), Brampton · BC Cancer Kelowna (Site 0112), Kelowna · McGill University Health Centre (Site 0106), Montreal · The Ottawa Hospital - General Campus (Site 0102), Ottawa · Centre intégré de santé et de services sociaux du Bas Saint-Laurent- Hôpital régional de Rimouski (Site 0100), Rimouski · BC Cancer - Victoria (Site 0109), Victoria
Registry updated 2026-10-13
NCT07509151
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Trial Treatment · Phase 3 · AstraZeneca
Calgary · Halifax · Hamilton · Montreal · Québec · Toronto · Vancouver
Registry updated 2026-10-06
NCT05006716
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Trial Treatment · Phase 1/2 · BeOne Medicines
Arthur Je Child Comprehensive Cancer Centre, Calgary · Cross Cancer Institute, Edmonton · Chu de Quebec Universite Laval, Hopital de Lenfant Jesus, Centre Integre de Cancerologie (Cic), Québec · Princess Margaret Cancer Centre, Toronto · British Columbia Cancer Agency the Vancouver Centre, Vancouver
Registry updated 2026-10-05
NCT06224309
Preliminary Assessment of [18F]BL40 in PET/CT Scans
Research · British Columbia Cancer Agency
BC Cancer, Vancouver
Registry updated 2026-10-01
NCT06542250
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Trial Treatment · Phase 1/2 · AstraZeneca
Calgary · Montreal · Toronto
Registry updated 2026-09-30
NCT06846671
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Trial Treatment · Phase 3 · BeOne Medicines
Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre, Greenfield Park · Juravinski Cancer Centre, Hamilton · London Health Sciences Centre, London · Jewish General Hospital, Montreal · The Ottawa Hospital Cancer Centre, Ottawa · Unite de Recherche Clinique Du Cisss Des Laurentides, SaintJerome
Registry updated 2026-09-28
NCT07277231
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Trial Treatment · Phase 3 · BeOne Medicines
Juravinski Cancer Centre, Hamilton · Jewish General Hospital, Montreal · Ciusss Nim Hscm, Montreal · Chu de Quebec Universite Laval, Hopital de Lenfant Jesus, Centre Integre de Cancerologie (Cic), Québec · Ciusss de Lestrie Chus, Sherbrooke · BC Cancer - Victoria, Victoria
Registry updated 2026-09-28
NCT05702645
A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
Research · Children's Oncology Group
This trial only enrols participants with Down syndrome
Children's Hospital, London
Registry updated 2026-08-25
NCT05254743
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Trial Treatment · Phase 3 · Loxo Oncology, Inc.
Royal Victoria Hospital-Montreal, Montreal · Hopital de L'enfant Jesus, Québec · Cancer Care Manitoba, Winnipeg
Registry updated 2026-08-17
NCT06104566
Global Trial in APG2575 for Patients With CLL/SLL
Trial Treatment · Phase 3 · Ascentage Pharma Group Inc.
Halifax
Registry updated 2026-06-18
NCT05963217
Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL
Trial Treatment · Phase 1 · University Health Network, Toronto
Princess Margaret Cancer Centre, Toronto
Registry updated 2026-06-09
NCT04260022
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Trial Treatment · Phase 1 · Ascentage Pharma Group Inc.
Princess Margaret Cancer Centre, Toronto
Registry updated 2025-11-05
NCT03765177
CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
Trial Treatment · Phase 1/2 · Ottawa Hospital Research Institute
The Ottawa Hospital - General Campus, Ottawa · Vancouver General Hospital, Vancouver · CancerCare Manitoba, Winnipeg
Registry updated 2025-08-14
NCT06862323
Time Restricted Eating in Haematological Malignancies
Trial Treatment · Phase 2 · British Columbia Cancer Agency
BC Cancer, Victoria
Registry updated 2025-06-13

All Chronic lymphocytic leukaemia trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error